BIO - Bio-Rad Laboratories Inc. (BIO) Q4 2023 Earnings Call Transcript
2024-02-15 18:54:02 ET
Bio-Rad Laboratories, Inc. (BIO)
Q4 2023 Earnings Conference Call
February 15, 2024, 5:00 PM ET
Company Participants
Edward Chung - Head, Investor Relations
Norman Schwartz - Chief Executive Officer
Andy Last - Executive Vice President and COO
Simon May - President, Life Science Group
Conference Call Participants
Patrick Donnelly - Citi
Jack Meehan - Nephron Research
Dan Leonard - UBS
Conor McNamara - RBC Capital Markets
Presentation
Operator
Good afternoon, ladies and gentlemen. And welcome to the Bio-Rad Fourth Quarter and Full Year 2023 Earnings Results Conference Call. At this time, all lines are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. [Operator Instructions]
I would now like to turn the conference over to Edward Chung. Please go ahead.
Edward Chung
Thanks, Jenny. Good afternoon, everyone, and thank you for joining us. Today, we will review the fourth quarter and full year 2023 financial results and provide an update on key business trends for Bio-Rad.
With me on the call today are Norman Schwartz, our Chief Executive Officer; Andy Last, Executive Vice President and Chief Operating Officer; and Simon May, President of the Life Science Group.
Before we begin our review, I would like to caution everyone that we will be making forward-looking statements about management’s goals, plans and expectations, our future financial performance and other matters.
These statements are based on assumptions and expectations of future events that are subject to risks and uncertainties. Our actual results may differ materially from these plans, goals and expectations.
You should not place undue reliance on these forward-looking statements and I encourage you to review our filings with the SEC where we discuss in detail the risk factors in our business. The company does not intend to update any forward-looking statements made during the call today....
Bio-Rad Laboratories, Inc. (BIO) Q4 2023 Earnings Call Transcript